Ερευνητικό υλικό ΕΚΠΑ

Severe chronic allergic (and related) diseases: A uniform approach - A MeDALL - GA2 LEN - ARIA position paper

Αγγλικά

Concepts of disease severity, activity, control and responsiveness to treatment are linked but different. Severity refers to the loss of function of the organs induced by the disease process or to the occurrence of severe acute exacerbations. Severity may vary over time and needs regular follow-up. Control is the degree to which therapy goals are currently met. These concepts have evolved over time for asthma in guidelines, task forces or consensus meetings. The aim of this paper is to generalize the approach of the uniform definition of severe asthma presented to WHO for chronic allergic and associated diseases (rhinitis, chronic rhinosinusitis, chronic urticaria and atopic dermatitis) in order to have a uniform definition of severity, control and risk, usable in most situations. It is based on the appropriate diagnosis, availability and accessibility of treatments, treatment responsiveness and associated factors such as comorbidities and risk factors. This uniform definition will allow a better definition of the phenotypes of severe allergic (and related) diseases for clinical practice, research (including epidemiology), public health purposes, education and the discovery of novel therapies. Copyright © 2012 S. Karger AG, Basel.

2012

Bousquet, J.
Anto, J.M.
Demoly, P.
Schünemann, H.J.
Togias, A.
Akdis, M.
Auffray, C.
Bachert, C.
Bieber, T.
Bousquet, P.J.
Carlsen, K.H.
Casale, T.B.
Cruz, A.A.
Keil, T.
Lodrup Carlsen, K.C.
Maurer, M.
Ohta, K.
Papadopoulos, N.G.
Roman Rodriguez, M.
Samolinski, B.
Agache, I.
Andrianarisoa, A.
Ang, C.S.
Annesi-Maesano, I.
Ballester, F.
Baena-Cagnani, C.E.
Basagaña, X.
Bateman, E.D.
Bel, E.H.
Bedbrook, A.
Beghé, B.
Beji, M.
Ben Kheder, A.
Benet, M.
Bennoor, K.S.
Bergmann, K.C.
Berrissoul, F.
Bindslev Jensen, C.
Bleecker, E.R.
Bonini, S.
Boner, A.L.
Boulet, L.P.
Brightling, C.E.
Brozek, J.L.
Bush, A.
Busse, W.W.
Camargos, P.A.M.
Canonica, G.W.
Carr, W.
Cesario, A.
Chen, Y.Z.
Chiriac, A.M.
Costa, D.J.
Cox, L.
Custovic, A.
Dahl, R.
Darsow, U.
Didi, T.
Dolen, W.K.
Douagui, H.
Dubakiene, R.
El-Meziane, A.
Fonseca, J.A.
Fokkens, W.J.
Fthenou, E.
Gamkrelidze, A.
Garcia-Aymerich, J.
Van Wijk, R.G.
Gimeno-Santos, E.
Guerra, S.
Haahtela, T.
Haddad, H.
Hellings, P.W.
Hellquist-Dahl, B.
Hohmann, C.
Howarth, P.
Hourihane, J.O.
Humbert, M.
Jacquemin, B.
Just, J.
Kalayci, O.
Kaliner, M.A.
Kauffmann, F.
Kerkhof, M.
Khayat, G.
Koffi N'Goran, B.
Kogevinas, M.
Koppelman, G.H.
Kowalski, M.L.
Kull, I.
Kuna, P.
Larenas, D.
Lavi, I.
Le, L.T.
Lieberman, P.
Lipworth, B.
Mahboub, B.
Makela, M.J.
Martin, F.
Martinez, F.D.
Marshall, G.D.
Mazon, A.
Melen, E.
Meltzer, E.O.
Mihaltan, F.
Mohammad, Y.
Mohammadi, A.
Momas, I.
Morais-Almeida, M.
Mullol, J.
Muraro, A.
Naclerio, R.
Nafti, S.
Namazova-Baranova, L.
Nawijn, M.C.
Nyembue, T.D.
Oddie, S.
O'Hehir, R.E.
Okamoto, Y.
Orru, M.P.
Ozdemir, C.
Ouedraogo, G.S.
Palkonen, S.
Panzner, P.
Passalacqua, G.
Pawankar, R.
Pigearias, B.
Pin, I.
Pinart, M.
Pison, C.
Popov, T.A.
Porta, D.
Postma, D.S.
Price, D.
Rabe, K.F.
Ratomaharo, J.
Reitamo, S.
Rezagui, D.
Ring, J.
Roberts, R.
Roca, J.
Rogala, B.
Romano, A.
Rosado-Pinto, J.
Ryan, D.
Sanchez-Borges, M.
Scadding, G.K.
Sheikh, A.
Simons, F.E.R.
Siroux, V.
Schmid-Grendelmeier, P.D.
Smit, H.A.
Sooronbaev, T.
Stein, R.T.
Sterk, P.J.
Sunyer, J.
Terreehorst, I.
Toskala, E.
Tremblay, Y.
Valenta, R.
Valeyre, D.
Vandenplas, O.
Van Weel, C.
Vassilaki, M.
Varraso, R.
Viegi, G.
Wang, D.Y.
Wickman, M.
Williams, D.
Wöhrl, S.
Wright, J.
Yorgancioglu, A.
Yusuf, O.M.
Zar, H.J.
Zernotti, M.E.
Zidarn, M.
Zhong, N.
Zuberbier, T.

International Archives of Allergy and Immunology

158

3

216-231

corticosteroid; omalizumab, allergic asthma; article; atopic dermatitis; chronic rhinosinusitis; chronic urticaria; clinical practice; clinical trial (topic); comorbidity; developing country; disease control; disease exacerbation; disease severity; follow up; genetic analysis; health care planning; human; nonhuman; practice guideline; priority journal; reimbursement; rhinitis; rhinoconjunctivitis; risk assessment; risk factor; sensitivity analysis; treatment response; urticaria, Asthma; Chronic Disease; Comorbidity; Dermatitis, Atopic; Humans; Hypersensitivity; Practice Guidelines as Topic; Rhinitis; Severity of Illness Index; Sinusitis; Urticaria

https://doi.org/10.1159/000332924

10.1159/000332924

https://pergamos.lib.uoa.gr/uoa/dl/object/3002960